Reported by Mrinal Banik
Agartala: Prices of 137 cancer medicines covering 543 brands and 1,364 formulations have been reduced by up to 96.45 per cent, offering significant relief to patients, Tripura Deputy Drugs Controller Subrata Das said on Wednesday.
The revised maximum retail prices (MRPs) came into effect on November 9 following a decision by the National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals of the Union Ministry of Chemicals and Fertilisers. The move is aimed at improving access to essential cancer medicines and easing the financial burden on patients.
Das said the price reductions apply to both injectable chemotherapy drugs and oral medicines. While several medicines have become cheaper by 78 to 82 per cent, some have witnessed a maximum reduction of 96.45 per cent.
Explaining the impact, Das cited the example of Anastrozole tablets. A strip of 10 tablets, which earlier cost Rs 695, is now priced at Rs 73. Similarly, the price of a 50 mg Fludarabine injection has dropped from Rs 14,235 to Rs 2,432.
The cost of Fulvestrant injections has also been reduced significantly. Previously priced at more than Rs 26,000, the injections will now cost Rs 5,491.
Das said the high cost of cancer treatment had forced some patients to discontinue medication midway. He expressed hope that the revised prices would ease their financial difficulties and help them continue treatment.
Pharmacies directed to implement revised prices
The Deputy Drugs Controller directed all medicine retailers and pharmacies across Tripura to strictly follow the revised MRPs. He clarified that medicines purchased at higher prices before November 9 must also be sold at the newly notified rates from that date.
To ensure that patients benefit from the reductions, the Drugs Control Administration, NPPA representatives and medical superintendents of cancer hospitals have launched joint awareness initiatives.
Awareness campaigns are also being conducted through pharmacies located within hospital premises, particularly AMRIT pharmacies. Posters, hoardings and other publicity measures will be introduced at major healthcare facilities, including ILS Hospitals and GB Cancer Hospital, to inform patients and their families about the revised prices.
The department is also encouraging consumers to use the ‘Pharma Sahi’ mobile application, developed by the Tripura State Pharmaceutical Pricing Monitoring Unit. The app allows users to check the notified prices of medicines before purchasing them.
Das urged patients and their family members to remain aware of the revised rates and report any instances of overcharging to the concerned authorities. He said pharmacies must not sell the medicines above their newly notified maximum retail prices.
